Gustave Roussy, Cancer Campus, Grand Paris clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 244 studies whose lead sponsor is Gustave Roussy, Cancer Campus, Grand Paris. 66 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Gustave Roussy, Cancer Campus, Grand Paris studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions Gustave Roussy, Cancer Campus, Grand Paris leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 244. Browse all 244 →
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingNCT05476939Phase 3
- Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingNCT07871864Phase 3
- Doxorubicin With or Without DT-7012 in Advanced Soft Tissue SarcomaNot yet recruitingNCT07802652Phase 2
- Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.Not yet recruitingNCT07808567Phase 2
- MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2RecruitingNCT05691608Not applicable
- Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples BankRecruitingNCT02666625
- Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)RecruitingNCT07016230Phase 2
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingNCT06298084Phase 1/2
- Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.Not yet recruitingNCT07802847Phase 4
- Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic DiseasesNot yet recruitingNCT07544225Phase 1
- Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced SonicationNot yet recruitingNCT07754006Phase 1
- Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/ResistanceRecruitingNCT07483983Phase 2
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
- Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory CancersRecruitingNCT05267912Not applicable
- KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal CancerNot yet recruitingNCT07622017Phase 2
- Cohort of Patients With Chronic Myelomonocytic LeukemiaRecruitingNCT07512882
- Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate CancerNot yet recruitingNCT07591467Phase 3
- Adjuvant Trial in Pancreatic Neuroendocrine TumorsNot yet recruitingNCT07591493Phase 3
- Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of CancerRecruitingNCT07436312Not applicable
- Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate CancerRecruitingNCT03819101Phase 3
- Helping Young People With Testicular Cancer Using Virtual and Extended RealityNot yet recruitingNCT07571499Not applicable
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.RecruitingNCT07303387Phase 2
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerRecruitingNCT07001618Phase 2
- Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young AdultsRecruitingNCT04477681
- Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsRecruitingNCT06907095Not applicable
- Prognostic and Predictive Biomarkers in Ovarian CancersRecruitingNCT03010124Not applicable
- Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine TumorNot yet recruitingNCT07471425
- Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial LesionsNot yet recruitingNCT07431502Phase 3
- Engineering Immune Organoids to Study Pediatric CancerRecruitingNCT05890781Not applicable
- Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young AdultsRecruitingNCT03983369Phase 3
- Gustave Roussy Cancer ProfilingRecruitingNCT04932525Not applicable
- Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial CancerRecruitingNCT06712472Phase 3
- PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave RoussyRecruitingNCT06479057
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerRecruitingNCT04965766Phase 2
- Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal AdenocarcinomaRecruitingNCT06402864Phase 3
- Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast CancerNot yet recruitingNCT06787118Phase 3
- A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast CancerRecruitingNCT06781996Phase 3
- Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid CancerRecruitingNCT06439888Phase 1/2
- A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerRecruitingNCT07159451Phase 2
- Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT SurgeryRecruitingNCT04842162Phase 2
- Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4
- STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related FatigueRecruitingNCT06505590Not applicable
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingNCT06840782Phase 3
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive InductionNot yet recruitingNCT07082452Phase 3
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingNCT04221035Phase 3
- Implementing Precision Medicine in cOmmunity HospiTALsRecruitingNCT05283044Not applicable
- Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyRecruitingNCT05692999Phase 3
- An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic TumorsRecruitingNCT05481502Not applicable
- Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell TumorsRecruitingNCT05874063Phase 3
- tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseRecruitingNCT06332274Phase 3